ArticleFrontiers in cell and developmental biology2026
Integrated metabolomics and mass spectrometry imaging reveal the Anti-Alzheimer's mechanisms of turmeric and curcumin.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: The phytochemical profiles of turmeric and turmeric residue were characterized using UPLC-MS/MS combined with bioinformatics analysis. An Aβ1-42-induced AD mouse model was established, and mass spectrometry imaging (AFAI-MSI) was applied to determine the optimal modeling time point. The therapeutic effects of curcumin and turmeric residue were evaluated through behavioral assessments, including the Morris water maze test, as well as histopathological and molecular analyses involving H&E staining, Nissl staining, immunofluorescence, and immunohistochemistry. Furthermore, non-targeted metabolomics was performed to identify metabolic alterations associated with treatment. Results: UPLC -MS/MS analysis identified 132 and 104 compounds in turmeric and turmeric residue, respectively, with 10 compounds showing significant differences in abundance between the two materials. AFAI-MSI analysis indicated that three weeks after Aβ1-42 injection represented an optimal time point for AD model establishment. Behavioral experiments demonstrated that both curcumin and turmeric residue significantly improved spatial learning and memory impairment in AD mice. Histological and molecular analyses revealed reduced neuronal damage and modulation of Aβ1-42 and Iba-1 expression in brain tissues. Metabolomic profiling identified 25 differential plasma metabolites and 38 differential brain metabolites following treatment. Pathway enrichment analysis suggested that these metabolic alterations were mainly associated with ether lipid, sphingolipid, glycerophospholipid, glutamate, purine, and arachidonic acid metabolism. Discussion: These findings demonstrate that curcumin and turmeric residue exert neuroprotective effects against AD-related pathological alterations by regulating metabolic disturbances and restoring metabolite homeostasis. The integration of chemical profiling, AFAI-MSI, and metabolomics provides new insights into the therapeutic potential and metabolic mechanisms of turmeric-derived resources in Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.